• RedHill Biopharma acquired exclusive commercialization rights to Ferring’s Rebyota and Clenpiq in a strategic GI portfolio shift.
• Upfront payment set at USD 12 million, with additional milestones and tiered royalties tied to net sales.
• Rebyota generated about USD 16.9 million in 2025 U.S. net sales; Clenpiq produced USD 20.6 million.
• Transaction funded from an earlier USD 18 million Talicia divestment, leaving RedHill with a larger commercial GI business.
• Rebyota license covers global commercialization; Clenpiq rights cover the U.S., with Ferring continuing to manufacture and supply Rebyota.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN38005) on September 01, 2026, and is solely responsible for the information contained therein.